FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients.
Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...
(Bloomberg) -- Bristol Myers Squibb Co. raised its 2024 profit forecast as demand for its new medicines suggested the company has gotten past a dip in performance. Adjusted earnings for the full year ...